Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model.
Emerging evidence suggests anti-cancer immunity is involved in the therapeutic effect induced by oncolytic viruses. Here we investigate the effect of Delta-24-RGD oncolytic adenovirus on innate and adaptive anti-glioma immunity.Mouse GL261-glioma model was set up in immunocompetent C57BL/6 mouse for...
Main Authors: | Hong Jiang, Karen Clise-Dwyer, Kathryn E Ruisaard, Xuejun Fan, Weihua Tian, Joy Gumin, Martine L Lamfers, Anne Kleijn, Frederick F Lang, Wai-Kwan Alfred Yung, Luis M Vence, Candelaria Gomez-Manzano, Juan Fueyo |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4020829?pdf=render |
Similar Items
-
The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
by: Anne Kleijn, et al.
Published: (2014-01-01) -
Oncolytic adenoviruses and immunopeptidomics: a convenient marriage
by: Marc Garcia‐Moure, et al.
Published: (2024-04-01) -
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
by: Naiara Martínez-Vélez, et al.
Published: (2019-05-01) -
Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens.
by: Sarah R Klein, et al.
Published: (2016-01-01) -
Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus
by: Ahmed Abdullah Al-Zaher, et al.
Published: (2018-03-01)